Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN versus MANDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN versus MANDOL.
CEFOXITIN vs MANDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-1 and PBP-3, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis. This leads to cell lysis and death. It is resistant to beta-lactamases produced by many Gram-negative and Gram-positive bacteria.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 0.7–1.1 hours (mean 0.8 h) in adults with normal renal function, extending to 5–10 hours in severe renal impairment (CrCl <10 mL/min).
Clinical Note
moderateCefoxitin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefoxitin."
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCefoxitin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoxitin."
Clinical Note
moderateCefamandole + Picosulfuric acid
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 85% of elimination; biliary excretion is minimal (<1%); fecal elimination is negligible.
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."